Vaxcyte Inc. (PCVX)
PCVX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$66.80
-5.45% on the day
Market cap
$10.5B
Large cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PCVX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001649094 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-08 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-10-09 |
| Latest proxy | DEFA14A | 2026-04-23 |
Source: SEC EDGAR submissions feed, 761 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.8% |
| 1 month | +14.0% |
| 3 months | +20.5% |
| Year to date | +46.3% |
| 1 year | +54.1% |
| From 52-week high | -8.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IBRX | ImmunityBio Inc. | $9.80 | -3.16% | $10.4B |
| TWST | Twist Bioscience Corporation | $151.33 | -0.35% | $10.0B |
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
| KRYS | Krystal Biotech Inc. | $321.16 | -3.29% | $9.5B |
| QGEN | Qiagen N.V. Common Shares | $45.44 | +0.29% | $9.4B |
| HALO | Halozyme Therapeutics Inc. | $109.62 | -1.31% | $12.4B |
| KYMR | Kymera Therapeutics Inc. | $106.68 | -4.82% | $8.9B |
| RGEN | Repligen Corporation | $175.42 | +1.69% | $8.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier